Michael Engsig
Chief Executive Officer Nykode
Michael joined Nykode Therapeutics in 2017. He is a broadly anchored pharmaceutical professional with extensive experience, from early-stage drug discovery to late-stage development and product launches in biotech and pharma and across all major geographical areas. His career history includes specialist and managerial roles at Takeda and Nycomed. Michael holds a civil engineering (MSc) degree in chemistry specializing in biotechnology from the Technical University of Denmark, and a Graduate Diploma in Business Administration (HD) in organization and leadership from the Copenhagen Business School (CBS).
Seminars
Wednesday 4th March 2026
Panel Discussion: Pharma & VC Perspectives on ASIT: Leveraging Early Safety Signals & Differentiated Platforms to Guide Investment & Strategic Partnerships
12:00 pm
- How do VCs and strategic partners assess differentiation among ASIT companies using nanoparticles, cell-based
- What development milestones -such as proof of infectious or bystander tolerance, early human safety signals, or scalable manufacturing – most strongly influence investment and partnership decisions?
- What do pharma see as the future challenges in the ASIT space?
